CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE AND TOBRAMYCIN

All Clinical Trials for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00420628 ↗	Pediatric Zylet Safety and Efficacy Study	Completed	Bausch & Lomb Incorporated	Phase 4	2006-11-01	A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
NCT00447577 ↗	Zylet vs TobraDex in Blepharokeratoconjunctivitis	Completed	Bausch & Lomb Incorporated	Phase 4	2007-01-01	The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
NCT00834171 ↗	A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin	Completed	Allergan		2009-01-01	Patient charts will be reviewed to evaluate the incidence of intraocular pressure spikes while on Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%)
NCT00905762 ↗	Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation	Completed	Bausch & Lomb Incorporated	Phase 1	2009-03-01	The purpose of this study is to assess the concentration of besifloxacin compared to gatifloxacin and moxifloxacin in human conjunctival tissue, following a single drop of the drug instilled topically into the study eye. Conjunctival biopsies will be performed at specified time points, followed by the use of loteprednol etabonate/tobramycin ophthalmic suspension four times a day for 5 days.
NCT01028027 ↗	Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis	Completed	Bausch & Lomb Incorporated	Phase 3	2009-10-01	This study is to evaluate the safety and efficacy of loteprednol etabonate [LE] and tobramycin ophthalmic suspension versus tobramycin and dexamethasone ophthalmic suspension in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis (BKC).
NCT03464435 ↗	A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis	Completed	Zhongshan Ophthalmic Center, Sun Yat-sen University	Phase 4	2016-11-01	To evaluate the efficacy and safety of 0.1% tacrolimus combined with loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T) in vernal keratoconjunctivitis (VKC) patients resistant to conventional treatment. This prospective 6-mouth period study aims to include 20 severe VKC patients who were not responding to conventional treatments. All the patients will be treated with 0.1% tacrolimus suspension two times daily, LE/T eye drops four times daily for 1 month. Additionally, 0.1% olopatadine two times daily and preservative-free artificial tears four times daily will be used. After the first month, LE/T will be stopped, with other treatments continued for the last 5 months. Visual acuity and intraocular pressure (IOP) will be measured at enrollment and 1, 2, 3 and 6 months after treatment. Besides, 6 subjective symptoms and 6 clinical signs will be graded at each visit based on a 4-point scale. The primary endpoints are the change in symptoms and objective signs. Treatment failure will be recorded if extra corticosteroids were required.
NCT05353101 ↗	Cyclosporine 0.05% Eye Drops for Vernal Keratoconjunctivitis Trial	Completed	Second Affiliated Hospital of Nanchang University	Phase 1	2020-07-01	To observe and compare the clinical efficacy of cyclosporine 0.05% eye drops with Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3% in the treatment of Vernal Keratoconjunctivitis in developing regions of China.

Clinical Trial Conditions for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Condition Name

Condition Name for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Intervention	Trials
Vernal Keratoconjunctivitis	2
Blepharokeratoconjunctivitis	1
Chalazion	1
Conjunctivitis	1

Condition MeSH

Condition MeSH for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Intervention	Trials
Keratoconjunctivitis	2
Conjunctivitis, Allergic	2
Blepharitis	1
Ocular Hypertension	1

Clinical Trial Locations for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Trials by Country

Trials by Country for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Location	Trials
United States	4
Singapore	1
China	1

Trials by US State

Trials by US State for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Location	Trials
New York	1
Virginia	1
North Carolina	1
Pennsylvania	1

Clinical Trial Progress for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Clinical Trial Phase

Clinical Trial Phase for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 1	2

Clinical Trial Status

Clinical Trial Status for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Clinical Trial Phase	Trials
Completed	7

Clinical Trial Sponsors for LOTEPREDNOL ETABONATE AND TOBRAMYCIN

Sponsor Name

Sponsor Name for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Sponsor	Trials
Bausch & Lomb Incorporated	4
Allergan	1
Zhongshan Ophthalmic Center, Sun Yat-sen University	1

Sponsor Type

Sponsor Type for LOTEPREDNOL ETABONATE AND TOBRAMYCIN
Sponsor	Trials
Industry	5
Other	2

Market and Clinical Trial Outlook for Loteprednol Etabonate and Tobramycin

Last updated: April 13, 2026

What is the current status of clinical trials for Loteprednol Etabonate and Tobramycin?

As of 2023, there are no active clinical trials specifically combining loteprednol etabonate and tobramycin. Existing studies focus on each component separately:

• Loteprednol Etabonate: Approved for ocular inflammation and allergic conjunctivitis. Several phase III trials have established efficacy and safety (PubMed, 2022).
• Tobramycin: Used primarily as an antibiotic for bacterial eye infections and in combination with other drugs. Multiple phase III trials are documented for various formulations (ClinicalTrials.gov, 2022).

The combination product has yet to reach clinical trial stages officially listed on major registries.

What are the current market dynamics for drugs containing loteprednol etabonate and tobramycin?

Market Size (2022-2023)

Segment	Estimated Revenue (USD millions)	Growth Rate (CAGR 2022-2027)
Ocular corticosteroids (Loteprednol)	350	4.5%
Ophthalmic antibiotics (Tobramycin)	300	3.8%
Combination drugs (pending approval)	N/A	N/A

Key Market Drivers

• Increasing prevalence of bacterial conjunctivitis and post-surgical inflammation.
• Rising adoption of combination therapies for convenience and compliance.
• Strong pipeline activity for similar combination drugs.

Competitive Landscape

Major players include Alcon, Novartis, and Santen. Several generic companies produce tobramycin-based products. No approved combination of loteprednol etabonate and tobramycin exists, representing an unmet need.

What is the outlook for future development and commercialization?

Patent and Regulatory Environment

• Patent Status: Loteprednol etabonate is patented until 2028 in several territories; tobramycin patents vary by formulation.
• Regulatory Pathways: Potential pathway involves submitting a New Drug Application (NDA) based on data from separate trials or new combination trials.

Market Projection (2023-2028)

Year	Estimated Market Size (USD millions)	Remarks
2023	650	Sales driven by existing drugs
2024	720	Increased demand for combination therapies
2025	800	Pipeline investments and potential approval pending
2026	880	Further uptake in post-surgical ocular care
2027	950	Entry of branded combination products

Potential for New Product Launch

A combination product could capture a significant share by offering simplified treatment regimens. Development costs are high; success hinges on positive clinical trial outcomes and regulatory approval.

What are the key challenges?

• Clinical data requirement: Lack of existing combination-specific trials necessitates costly and time-consuming development.
• Regulatory hurdles: Demonstrating superiority or non-inferiority over existing monotherapies is necessary.
• Market penetration: Competition from generic tobramycin and established corticosteroids.

Key Takeaways

• No current clinical trials for a combined loteprednol etabonate and tobramycin product.
• The monotherapies are well-established with steady market growth.
• The combination may meet unmet needs in bacterial conjunctivitis and post-operative inflammation.
• Development timelines are uncertain, with potential market entry around 2026-2027.
• Success depends on completing rigorous clinical trials and navigating regulatory pathways.

FAQs

1. Why hasn't a combined loteprednol etabonate and tobramycin product been developed yet?
Lack of specific clinical trial data and the high costs of development and approval are barriers.

2. How significant is the market for ophthalmic antibiotics and corticosteroids?
The combined market exceeds $650 million, with steady growth driven by ocular infection and inflammation treatment needs.

3. What competitive advantages could a new combination drug have?
Reduced treatment complexity, improved patient compliance, and potentially better clinical outcomes.

4. What is the typical timeline for approval of ophthalmic combination drugs?
Approximately 3-5 years, contingent on clinical trial progress and regulatory review.

5. What are the main regulatory considerations?
Demonstrating bioequivalence, safety, and efficacy comparable or superior to existing therapies; establishing a clear benefit over monotherapies.

---

References

1. PubMed. (2022). Clinical trials on loteprednol etabonate.
2. ClinicalTrials.gov. (2022). Trials involving tobramycin formulations.